Evidence map›Paper›PMID 22080065›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2012

Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.

Sarah J Storr, Sabreena Safuan, Angana Mitra, Faye Elliott, Christopher Walker, Mark J Vasko, Bernard Ho, Martin Cook, Rabab A A Mohammed, Poulam M Patel and 3 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The tumor immune microenvironment in primary cutaneous melanoma.Archives of dermatological research · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Sarah J StorrAcademic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK.
Sabreena Safuan
Angana Mitra
Faye Elliott
Christopher Walker
Mark J Vasko
Bernard Ho
Martin Cook
Rabab A A Mohammed
Poulam M Patel
Ian O Ellis
Julia A Newton-Bishop
Stewart G Martin
Nottingham University Hospitals NHS Trust · GBUniversity of Nottingham · GBSt James's University Hospital · GBUniversity of Leeds · GBRoyal Surrey County Hospital · GB

Funding

Cancer Research UK 10589Cancer Research UK 11963Cancer Research UK C588/A4994Cancer Research UK C8216/A6129Cancer Research UK C8216/A8168
6 · The paper itself

Abstract

The aims of this study were to investigate the role of vascular invasion (blood and lymphatic), vessel density and the presence of tumour-associated macrophages as prognostic markers in 202 cutaneous melanoma patients. Sections of primary melanoma were stained with lymphatic-specific antibody D2-40 to assess lymphatic vessel invasion and density in intratumoural and peritumoural areas; an antibody against endothelial marker CD34 was used to determine blood vessel invasion and density, and an antibody against CD68 was used to determine macrophage counts. Immunohistochemically determined vascular invasion (combined blood and lymphatic) was compared with that determined using haematoxylin and eosin (H&E) staining. The use of immunohistochemistry increased detection of vascular invasion from 8-30% of patients, and histological exam of H&E-stained tissue was associated with a false positive rate of 64%. Lymphatic vessel invasion occurred at a much higher frequency than blood vessel invasion (27 and 4% of patients, respectively). Although immunohistochemically detected vessel invasion was significantly associated with histological markers of adverse prognosis, such as increased Breslow thickness, ulceration and mitotic rate (all P<0.001), no associations with relapse-free or overall survival were observed. High macrophage counts were significantly associated with markers of aggressive disease, such as Breslow thickness, ulceration and mitotic rate (P<0.001, P<0.001, P=0.005, respectively), and lymphatic vessel invasion and high microvessel density (P=0.002 and P=0.003, respectively). These results suggest that vascular invasion is more accurately detected using immunohistochemistry and occurs predominantly via lymphatic vessels. The association of vessel characteristics with histological characteristics of the primary melanoma provides evidence for their biological importance in melanoma, but that they were not associated with clinical outcome attests to the value of existing histological prognostic biomarkers. We note that a high macrophage count may be associated with neovascularisation and primary tumour growth, and may also promote invasion through lymphatic vessels.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntigens, CDAntigens, CD34Antigens, Differentiation, MyelomonocyticBiomarkers, TumorBlood VesselsCase-Control StudiesCD68 MoleculeChi-Square DistributionDisease-Free SurvivalEnglandFalse Positive ReactionsAntibodies, Monoclonal, Murine-DerivedAntigens, CDAntigens, CD34Antigens, Differentiation, MyelomonocyticBiomarkers, TumorCD68 antigen, humanCD68 Moleculemonoclonal antibody D2-40

Identifiers

PMID22080065
PMCPMC3318158
OpenAlexW2119754704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.